BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma

Cancer

Volumn 119, Issue 2, 2013, Pages 332-338

  Pennington, Kathryn P ^a   Walsh, Tom ^a   Lee, Ming ^a   Pennil, Christopher ^a   Novetsky, Akiva P ^b   Agnew, Kathy J ^a   Thornton, Anne ^a   Garcia, Rochelle ^a   Mutch, David ^b   King, Mary Claire ^a   Goodfellow, Paul ^b   Swisher, Elizabeth M ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BRCA1 gene; BRCA2 gene; Lynch syndrome; molecular genetics; uterine serous carcinoma

Indexed keywords

BRCA1 PROTEIN; CHECKPOINT KINASE 2; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MSH2; PROTEIN MSH6; PROTEIN P53;

ARTICLE; BREAST CARCINOMA; CHEK2 GENE; CONTROLLED STUDY; DELETION MUTANT; FAMILIAL CANCER; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HISTOLOGY; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; LYMPHOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; MSH2 GENE; MSH6 GENE; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; PMS2 GENE; PRIORITY JOURNAL; TP53 GENE; TUMOR SUPPRESSOR GENE; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA;

ADULT; AGED; BRCA1 PROTEIN; CARCINOMA; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE FREQUENCY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84872068762     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27720     Document Type: Article

References (28)

1. Walsh T, Casadei S, Lee M, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011; 108: 18032-18037.
2. Boruta DM 2nd, Gehrig PA, Fader AN, Olawaiye AB,. Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol. 2009; 115: 142-153.
3. Boruta DM 2nd, Gehrig PA, Groben PA, et al. Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference? Cancer. 2004; 101: 2214-2221.
4. Hornreich G, Beller U, Lavie O, Renbaum P, Cohen Y, Levy-Lahad E,. Is uterine serous papillary carcinoma a BRCA1-related disease? Case report and review of the literature. Gynecol Oncol. 1999; 75: 300-304.
5. Biron-Shental T, Drucker L, Altaras M, Bernheim J, Fishman A,. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. Eur J Surg Oncol. 2006; 32: 1097-1100.
6. Levine D, Lin O, Barakat R, et al. Risk of endometrial carcinoma associated with BRCA mutation. Gynecol Oncol. 2001; 80: 395-398.
7. Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine serous carcinoma-still a debate. Int J Gynecol Cancer. 2010; 20: 1531-1534.
8. Goshen R, Chu W, Elit L, et al. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? Gynecol Oncol. 2000; 79: 477-481.
9. Geisler J, Sorosky J, Duong H, et al. Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. Gynecol Oncol. 2001; 83: 501-503.
10. Meyer LA, Broaddus RR, Lu KH,. Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. Cancer Control. 2009; 16: 14-22.
11. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66: 7810-7817.
12. Ollikainen M, Abdel-Rahman WM, Moisio AL, et al. Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? J Clin Oncol. 2005; 23: 4609-4616.
13. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci U S A. 2003; 100: 5908-5913.
14. Walsh T, Lee MK, Casadei S, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A. 2010; 107: 12629-12633.
15. Nord AS, Lee M, King MC, Walsh T,. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics. 2011; 12: 184-194.
16. National Human Genome Research Institute. Breast Cancer Information Core database. http://research.nhgri.nih.gov/bic/.
17. National Heart, Lung, and Blood Institute, Exome Sequencing Project. Exome Variant Server. http://evs.gs.washington.edu/EVS/.
18. International Agency for Research on Cancer. IARC TP53 Database, version R15. http://www-p53.iarc.fr/. Updated November 2010.
19. Soussi T, Kato S, Levy PP, Ishioka C,. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat. 2005; 25: 6-17.
20. Roeb W, Higgins J, King MC,. Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet. 2012; 21: 2738-2744.
21. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 2011; 43: 879-882.
22. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010; 42: 410-414.
23. Rafnar T, Gudbjartsson DF, Sulem P, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011; 43: 1104-1107.
24. Ford D, Easton DF, Peto J,. Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 1995; 57: 1457-1462.
25. Dewdney SB, Kizer NT, Andaya AA, et al. Uterine serous carcinoma: increased familial risk for Lynch-associated malignancies. Cancer Prev Res. 2012; 5: 435-443.
26. Kleihues P, Schäuble B, zur Hausen A, Estève J, Ohgaki H,. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol. 1997; 150: 1-13.
27. Birch JM, Alston RD, McNally RJ, et al. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene. 2001; 20: 4621-4628.
28. Nichols KE, Malkin D, Garber JE, Fraumeni JF Jr, Li FP,. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001; 10: 83-87.